乌鸦传媒

<乌鸦传媒 class="page-title">Meeting Coverage

ASCO Expert Roundtable: Immunotherapy

<乌鸦传媒 class="page-description">Expert Video Roundtable from the American Society of Clinical Oncology
Experts Discuss the Latest Studies on ADCs for Lung Cancer at ASCO 2024

Panelists talk about where lung cancer research will be in 5 years

image
<乌鸦传媒 class="section_title">Latest ASCO Expert Roundtable: Immunotherapy Meeting Coverage
Experts Discuss Groundbreaking Advances in EGFR-Mutant Lung Cancer

Discussion highlights insights from the LAURA trial and others on emerging treatments

July 3, 2024
In CROWN, Lorlatinib Shows Longest PFS in ALK-Positive Lung Cancer

"At 5 years, well more than half of the patients continue to respond"

June 26, 2024
Durvalumab Consolidation a 'Breakthrough' in Limited-Stage SCLC

Roy Herbst, MD, PhD, leads a roundtable talk that also reviews the recent tarlatamab approval

June 18, 2024
Predictions on the Future of Lung Cancer and Immunotherapy

Our roundtable of experts answer a "lightning round" of topics from screening to biomarkers

July 13, 2023
Adjuvant Osimertinib as a Standard Therapy for EGFR-Positive NSCLC

Roy Herbst, MD, PhD, leads a roundtable discussion on the ADAURA OS data

July 6, 2023
Adjuvant Immunotherapy in Early-Stage NSCLC

Roy Herbst leads a discussion with Julie Brahmer and Sarah Goldberg

June 29, 2023
The Role of Immunotherapy in Early-Stage NSCLC

Roy Herbst, MD, PhD, leads a discussion on the positive trials in the early-treatment setting

June 22, 2023
<乌鸦传媒 class="section_title"> Latest Oncology/Hematology Meeting Coverage